Evaluation of Hepatoprotective Effect of a Polyherbal Megakutki against Paracetamol-Induced Hepatotoxicity

Asha Elizabeth Giri¹, Vanishree Rao¹, Sandeep Singhal¹, Karthik Gourishetti¹, Subhankar Biswas¹, Krishnadas Nandakumar¹, Mallikarjuna Rao Chamilamudi¹, Jeetesh Dave², Rakesh Dave², Suhani Sumalatha³, Nitesh Kumar¹, ⁴,*

¹Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA.  
²Umalaxmi Organics Pvt. Ltd., Agro Food Park Industrial Area, Boranada, Jodhpur, Rajasthan, INDIA.  
³Department of Anatomy, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, INDIA.  
⁴Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hajipur, Export Promotions Industrial Park (EPIP), Industrial Area Hajipur, Vaishali, BIHAR, INDIA.

ABSTRACT

Background: Megakutki® (MK) is a polyherbal preparation of 11 standardized extracts that are individually proven for hepatoprotection scientifically. Aim: Study evaluated MK’s hepatoprotective potential against paracetamol (PCM) in in-vitro on Hep G2 cells using cell viability, cell cycle analysis and apoptotic studies and in in-vivo in Wistar rats using liver function tests, histological and DNA fragmentation study. Materials and Methods: In in-vitro studies, IC₅₀ (50% inhibition in viability) values of silymarin, MK and PCM were found out by MTT assay. In-vitro hepatoprotection was found out by pretreating the cells with below-IC₅₀ concentrations of MK and silymarin for 24h followed by PCM (at IC₅₀ concentration) challenge for next 24h and % viability was evaluated using MTT assay. Same treatment protocol was followed for cell cycle analysis and apoptotic studies (100 and 200 µg/ml for MK and 50 µg/ml for silymarin and 40µM for PCM). In in-vivo study, animals were grouped in six, namely, vehicle, PCM control, silymarin (50 mg/kg, standard), MK (100 and 300 mg/kg) groups. Animals were dosed for 8 days while they were challenged on day 6 (except vehicle group) with PCM (2.75 g/kg p.o). On day 8, blood and livers were collected under anaesthesia and analyzed. Results: In-vitro results showed hepatoprotection by MK and silymarin by inhibition of PCM-induced cell death apoptotic cells percentage. In in-vivo study, MK and silymarin reversed the altered liver function and elevated oxidative stress markers (catalase, SOD, GSH, total thiols and lipid peroxidation) compared to paracetamol alone group. Both MK and silymarin decreased the percentage of DNA fragmentation and histopathological changes in liver tissue compared to the PCM group. Conclusion: The in-vitro and in-vivo studies showed the hepatoprotective effect of MK by the prevention of PCM-induced induction of oxidative stress by its antioxidant potential thereby preventing PCM-induced DNA damage.

Key words: Megakutki, Paracetamol, Hepatoprotection, Cell viability, Hep G2.

INTRODUCTION

Liver is an important organ to regulate key biochemical events that helps in nutrient supply, growth, protection against xenobiotics, energy supply and to fight against pathogens. Due to its multifaceted functions, liver is one of the main organs exposed to various toxicity hazards. Hepatocytes, the functional units of the liver, combat these hazards with the tremendous regenerating capacity.¹ Despite this regenerating capacity, liver damage is a major disease affecting people worldwide. More than 900 drugs, toxins and herbs have been found to cause hepatotoxicity and
also making it one of the main reasons for the drug withdrawal. There is a lack of drugs in the modern system of medicine which can treat the hepatotoxicity condition. The treatment approach mainly depends on the symptoms by the use of antibiotics, anti-viral drugs, interferon, immunosuppressants and corticosteroids. However, these drugs mainly treat the cause and do not provide any support to the liver for regeneration. There is a preference for an alternative system or traditional systems of medicines to treat liver ailments, due to the unavailability of regenerators in the modern system of medicine. That is why drugs like silymarin have gained popularity as a regenerator or protector. Considering the importance of herbal medicine in the treatment of liver ailment and their popularity in developing and underdeveloped countries, this study was planned to assess a combination of known hepatoprotective extracts against paracetamol (PCM) induced hepatotoxicity. This particular model was chosen since PCM is one of the well-known and common inducers of fulminant hepatic failure. Toxicity to the liver cells is brought about by a metabolite of PCM namely, N-acetyl-p-benzoquinone imine (NAPQI), which initially binds to copious mitochondrial proteins leading to series of events like mitochondrial pore opening (membrane permeability transition), swelling of the matrix and lysis of outer membrane. This lysis and increased permeabilization results in the release of endonucleases which gets translocated to the nucleus and causes fragmentation of nuclear DNA.

Megakutki, a polyherbal formulation, consisting of 11 standardized extracts namely Picrorrhiza kurroa, Andrographis paniculata, Tinospora cordifolia, Phyllanthus niruri, Boerhavia diffusa, Phyllanthus emblica, Terminalia billerica, Terminalia chebula, Eclipta alba, Picrorrhiza officinalis, and Piper longum which are already known for their hepatoprotective individuality. These extracts are individually rich in polyphenols and tannins, which are powerful antioxidants. They can react with active oxygen radicals, such as superoxide anion radicals, hydroxyl radicals and lipid peroxide radicals and inhibit lipid oxidation which can prevent cell damage. Thus, the present study was aimed to determine the in vitro hepatoprotective effect of the formulation against paracetamol in rats and to explore the in vitro preventing effect of this formulation against paracetamol-induced apoptosis in Hep G2 cell lines. Further, the study was also designed to address the safety of the formulation in acute toxicity study.

MATERIALS AND METHODS

Chemicals, formulations and Drugs

MK was supplied by Umalaxmi Organics Private Limited, Jodhpur, India. Megakutki® (MK) was a polyherbal preparation where each capsule consisted 11 standardized extracts namely Picrorrhiza kurroa – 40 mg; Andrographis paniculata - 12.5 mg; Phyllanthus niruri -12.5 mg; Boerhavia diffusa – 25 mg; Tinospora cordifolia - 10 mg; Phyllanthus emblica – 75 mg; Terminalia billerica – 25 mg; Terminalia chebula – 25 mg; Eclipta alba – 25 mg; Zingiber officinalis – 25 mg; Piper longum - 25 mg. Cell culture media, growth factors, buffers and reagents were purchased from Himedia, Laboratories Pvt. Ltd, India. Paracetamol (PCM) was provided as a gift sample from Lupin Limited, Pune, India. The diagnostic kits used for biochemical estimation of serum samples were purchased from Aspen Laboratories, India. The other chemicals used in the study were from SD fine chemicals, Mumbai, India.

Cell lines and animals

The human liver cancer cell line (Hep G2) was purchased from National Center for Cell Sciences, India. The cells were revised and sub-cultured in the tissue culture lab of the Pharmacology Department of Manipal College of Pharmaceutical Sciences, India. The acute toxicity study and hepatoprotective study procedures were approved by the Ethical Committee and approved (IAEC/KMC/932015). Inbred male and female Wistar rats of 10 to 12 weeks old were used in this study. They were maintained under standard animal house husbandry conditions as mentioned in the Committee for the Purpose of Control and Supervision of Experiments on Animals, India.

Phytochemical analysis of formulation

The polyherbal formulation was subjected to quantitative analysis for total phenolic content, total flavonoid content and total tannin content as per the standard procedures.

In-vitro Hepatoprotective Study in Hep G2 Cell line

Cell viability assay for dose determination of MK and PCM

A dose-dependent toxicity profile (IC₅₀) was performed for MK and paracetamol in Hep G2 cells. Cytoprotection study was evaluated using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay. After 24 h of seeding the cells, it was exposed to different concentrations of MK (25 to 400 µg/ml) or paracetamol (6.25 to 100 mM). The viability of cells was evaluated after 72 h of exposure of MK and 48 h after PCM by adding MTT (20 µl, 5 mg/mL) followed by 100 µl DMSO for solubilization. The color was visualized at 540 nm using ELx800 plate reader of BioTek Instruments Inc., USA.

In-vitro Hepatoprotective studies using MTT assay

The protective effect of MK was evaluated against PCM (40 mM) in Hep G2 cell line using MTT assay. Two concentrations of MK were selected to test the protective effect of MK against PCM-induced hepatotoxicity which
were 100 and 200 µg/ml. Following 24 h of incubation with MK, toxicant PCM (40mM) was added and incubated for 48 h. Cytotoxicity was assessed using MTT assay.\textsuperscript{19}

**Cell cycle analysis of Hep G2 cells**

Exponentially growing cells were harvested from tissue culture flask and grown in sterile 6 well plates for 24 hrs. After 24 hr, cells were treated with two doses of Megakutki and the plates were further incubated for 24 hr. After 24 hr, cells were treated with PCM and were further incubated for 24 hrs. After 72 hr, the media was aspirated and the plates were washed twice with phosphate buffer saline (PBS). Next, the cells were trypsinized, suspended in PBS and were centrifuged. The obtained pellet was suspended in ice-cold ethanol (70%) and incubated for 1 hr in 4°C. After incubation, cells were again centrifuged and the pellet resuspended in PBS. Cells were centrifuged again and the pellet resuspended in PBS containing Propidium iodide for 20 min in dark. After 20 min cells were analyzed using a flow cytometer.

**Apoptosis/necrosis estimation in Hep G2 cells by Acridine orange/Ethidium bromide (AO/EB) staining**

Hep G2 cells were incubated with PCM (40mM), either alone or in combination with MK (at 100 and 200 µg/ml, 24 h incubation prior to PCM exposure) in 6 well plates. After 24 h of incubation, cells were washed by PBS and fixed at room temperature with cold ethanol (1 ml for 10 min). After that 1 ml AO/EB reagent stain per well was added and incubated for 10 min at 37°C. The morphological examination of cells (apoptotic vs necrotic cells) were performed using Inverted microscope with fluorescence filters.\textsuperscript{20}

**In-vivo hepatoprotective activity against PCM-induced hepatotoxicity in rats**

Thirty-six female Wistar rats were divided into 5 groups consisting of 6 animals in each group. Group 1 was treated orally with 0.25% carboxymethylcellulose solution (CMC) at a volume of 1ml/100g of the rat. Group 2 was treated with CMC like Group 1 rats. Group 3 rats received silymarin (50 mg/kg, p.o), while Group 4 and 5 received MK at 100 and 300 mg/kg p.o respectively for 8 days. On the 6\textsuperscript{th} day, all the rats except group 1 were administered with a single-dose of PCM (2.75 g/kg, p.o). On the 8\textsuperscript{th} day, the animals were anesthetized, blood samples were removed by cardiac puncture. The blood samples were processed for hematological estimations and to obtain serum. The serum samples were used to estimate aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin and total protein. A portion of the liver was used for histological examination and the remaining part was homogenized in 10% potassium chloride solution.

The homogenate was used to estimate total protein, GSH, Catalase, superoxide dismutase, thiobarbituric acid and total thiols as per our routine laboratory methods.\textsuperscript{21} Subsequently, part of the liver homogenate was subjected to DNA isolation by chloroform: isoamyl alcohol extraction method. The DNA was precipitated by the addition of ethanol. Then the DNA was subjected to gel electrophoresis to analyze the DNA fragmentation pattern with PCM treatment and MK treatments.\textsuperscript{22}

**Acute oral toxicity in rats**

Acute oral toxicity of MK was performed according to OECD guidelines 425. Briefly, the nulliparous and non-pregnant females of 10 to 12 weeks old were used in this study. Initially, a single dose of 2000 mg/kg was given to a rat and was closely observed for signs of toxicity, survival or death for 14 days.

**Statistical Analysis**

Data are expressed as mean ± SEM. Statistical differences in means were determined using one-way analysis of variance followed by Tukey’s post test using a trial version of Prism software (Version 5.03, GraphPad Software Inc., La Jolla, CA, USA). A probability value of less than \(p < 0.05\) was considered significant.

**RESULTS**

**Phytochemical Estimations**

MK had a high amount of phenolic and tannin content. In 200 µg of formulation, the total phenolic content was 110.35 ± 1.83 µg as per gallic acid equivalent while the tannin content was 57.73 ± 0.47 µg as per tannic acid equivalent.

**Effect of MK, silymarin and PCM on Hep G2 cell line**

MK, silymarin and PCM produced a dose-dependent reduction in cell viability of Hep G2 cell line. The IC\textsubscript{50} values of silymarin, MK and PCM were found to be 106.4µg/ml, 414.2 µg/ml and 35.98 µM (Figure 1). More than 70% of the cells are confluent at 100 and 200 µg/ml doses of MK while similar observations were seen at 50 µg/ml of silymarin. Based on these observations, the hepatoprotective doses for MK were selected as 100 and 200 µg/ml whereas, for silymarin 50 µg/ml. Almost 50% of the cells died with 40 mM concentration of PCM which was selected as a toxic concentration of PCM.

**Protective effect of MK against PCM and inhibition of apoptosomes in Hep G2 cell lines**

PCM at 40 mM concentration caused 49.37±1.56 percent cell death in Hep G2 cell line. A dose-dependent protection against PCM toxicity was observed for silymarin and MK. Pretreated with MK (100 and 200
µg/ml) and silymarin (50 µg/ml) prevented the cell death against PCM (40 mM). Maximum protection was seen at 50 µg/ml of MK [Table 1]. Further, AO/EB staining revealed that PCM significantly increased the percentage of apoptotic cells to about 91.32 ± 0.688. Treatment with MK at both dose levels and silymarin significantly reduced the percentage of apoptotic cells against the PCM challenge [Figure 2].

**Effect of MK on acute oral toxicity**

Single-dose treatment with MK at 2000 mg/kg did not cause any behavioral change or death in any of the rats.

**Liver function tests**

PCM significantly \( (p<0.05) \) elevated the AST value with respect to vehicle control group. Treatment with silymarin (standard) and test drug Megakutki at both doses exhibited a significant \( (p<0.05) \) reduction in AST levels with respect to the PCM alone treated group. However, no dose-dependent relationship was observed in Megakutki’s treatment.

A similar effect was seen on the ALT parameters, PCM treatment in the disease control group showed a significant \( (p<0.05) \) elevation in ALT levels with respect to the vehicle control group. Silymarin and the test

---

**Table 1: In-vitro Hepatoprotection on Hep G2.**

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Conc.(µg/ml)</th>
<th>% Cell Viability in presence of Paracetamol (40mM)</th>
<th>Drug name</th>
<th>Conc.(µg/ml)</th>
<th>% Cell Viability in presence of Paracetamol (40mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silymarin (Std)</td>
<td>15.18</td>
<td>76.6 ± 6.51</td>
<td>Megakutki</td>
<td>25</td>
<td>66.95 ± 2.53</td>
</tr>
<tr>
<td></td>
<td>31.25</td>
<td>64.3 ± 1.2</td>
<td></td>
<td>50</td>
<td>70.18 ± 1.31</td>
</tr>
<tr>
<td></td>
<td>62.5</td>
<td>43.2 ± 2.42</td>
<td></td>
<td>100</td>
<td>65.79 ± 1.96</td>
</tr>
<tr>
<td></td>
<td>125</td>
<td>59.2 ± 1.04</td>
<td></td>
<td>200</td>
<td>54.82 ± 1.6</td>
</tr>
<tr>
<td></td>
<td>250</td>
<td>42.9 ± 2.82</td>
<td></td>
<td>400</td>
<td>47.22 ± 0.52</td>
</tr>
</tbody>
</table>

% Cell Viability is represented in terms of means±SEM of three readings. PCM at 40 mM concentration showed 49.37±1.56 percent cell death.
drug Megakutki at both doses resulted in a significant \((p<0.05)\) decrease in ALT levels with respect to the PCM group. However, no dose-dependent relationship was observed in Megakutki’s treatment.

ALP also showed a similar trend. ALP levels in the PCM group elevated significantly \((p<0.05)\) with respect to the vehicle control group. Silymarin and the test drug Megakutki at 100 mg/kg exhibited a significant \((p<0.05)\) decrease in the ALP levels with respect to the PCM group. PCM treatment significantly \((p<0.05)\) raised Total Bilirubin levels with respect to the control group. Silymarin and the test drug Megakutki at both doses showed a significant \((p<0.05)\) decrease in total bilirubin levels with respect to the PCM group. However, no dose-dependent relationship was observed in Megakutki treatment [Table 2].

**Anti-oxidant measurements**

The catalase activity of the PCM group significantly \((p<0.05)\) minimized with respect to the vehicle group. The standard (silymarin) treatment and the test drug Megakutki at both doses significantly increased the catalase activity with respect to the PCM group. No significant \((p<0.05)\) difference was seen between Megakutki at 100mg/kg and 300mg/kg. A similar trend like catalase levels was seen in the SOD activity, GSH and total thiols levels.

Lipid Peroxidation activity (assessed in terms of MDA level) of the PCM group significantly \((p<0.05)\) increased with respect to the vehicle group. Silymarin and Megakutki at both dose levels exhibited a significant \((p<0.05)\) reversal in the lipid peroxidation levels with respect to the PCM group. No significant \((p<0.05)\) difference was seen between Megakutki at 100mg/kg and 300mg/kg [Table 3].

**DNA fragmentation**

The % of DNA fragmentation in the PCM treated group was found to be the highest within the 5 groups. PCM showed 69% of fragmentation towards the lower side which indicates apoptosis. The drugs silymarin and both doses groups of Megakutki were found to decrease the % fragmentation towards the lower side. Therefore, it showed protection against PCM induced apoptosis [Figure 3].

**Histology of Liver**

The sections of normal control showed the normal structure of hepatocytes with classic lobule structure. The sections of the liver treated with PCM showed immense necrosis and neutrophil infiltration with the deranged central vein. The treatment groups sections

---

**Table 2: Liver Function Test.**

<table>
<thead>
<tr>
<th>Group Name</th>
<th>AST</th>
<th>ALT</th>
<th>ALP</th>
<th>Total Bilirubin</th>
<th>Direct Bilirubin</th>
<th>Total Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>160.90 ± 13.04</td>
<td>44.47 ± 2.89</td>
<td>89.92 ± 3.03</td>
<td>0.157 ± 0.058</td>
<td>0.104 ± 0.037</td>
<td>7.07 ± 0.31</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>280.99 ± 12.25#</td>
<td>252.19 ± 29.65#</td>
<td>139.92 ± 11.79</td>
<td>0.312 ± 0.063#</td>
<td>0.104 ± 0.039</td>
<td>6.99 ± 0.21</td>
</tr>
<tr>
<td>Silymarin 50mg/kg</td>
<td>227.59 ± 18.81*</td>
<td>128.34 ± 23.67*</td>
<td>81.2 ± 8.70*</td>
<td>0.142 ± 0.039*</td>
<td>0.100 ± 0.031</td>
<td>6.945 ± 0.14</td>
</tr>
<tr>
<td>Megakutki -100mg/kg</td>
<td>211.59 ± 17.78*</td>
<td>125.08 ± 18.34*</td>
<td>74.62 ± 20.2*</td>
<td>0.13 ± 0.043*</td>
<td>0.104 ± 0.048</td>
<td>6.586 ± 0.301</td>
</tr>
<tr>
<td>Megakutki – 300mg/kg</td>
<td>194.89 ± 18.64*</td>
<td>130.32 ± 17.11*</td>
<td>129.92 ± 10.21</td>
<td>0.172± 0.009*</td>
<td>0.104 ± 0.034</td>
<td>6.41 ± 0.35</td>
</tr>
</tbody>
</table>

All the values are mean ± SEM, where #p<0.05 compared to the normal group and *p<0.05 compared to paracetamol control.

---

**Figure 3: Effect of treatments on DNA fragmentation.**
of the liver showed some neutrophil infiltration and normal central vein structure [Figure 4].

DISCUSSION

Phytochemical estimation of Megakutki showed high content of polyphenols and tannin which could contribute to the anti-oxidant property of the polyherbal formulation. The hepatoprotection studies were conducted in-vitro and in-vivo to assess its hepatoprotective potential and the underlying mechanism involved for the same. In-vitro studies were done to evaluate the hepatoprotective effect of the drug on Hep G2 cells.

The in-vitro studies do not exactly reflect the mechanisms of hepatoprotection, because the in-vitro systems are associated with multiple growth signaling mechanisms such as insulin, growth hormones, IGF, etc., which are missing in in-vitro systems such as in hepatoprotection study in HepG2 cell line. However, the use of in-vitro studies plays an important role in the evaluation of the hepatoprotective effect of drugs against toxicants without much interference from the above-mentioned growth signals.

MTT is a chemical that easily permeates the cell membrane and gets metabolized by the mitochondrial enzyme (succinate dehydrogenase) to formazan, a violet-colored substance. This principle have been used commonly to evaluate the difference in the percentage of viability cells by the drugs at various concentrations in the presence of various toxicants. In the present study, MTT assay was used to evaluate the hepatoprotective action of Megakutki on HepG2 cells. Firstly, the IC50 values of the drugs and PCM were assessed. For hepatoprotection study, the toxicant was used at IC50 value while protectants were used at concentrations below IC50 values. The drug concentration was fixed below the IC50 value (400 μg/mL) and that of PCM at 40 mM. Treatment with MK prevented PCM-induced toxicity in Hep G2. Based on in vitro protection study, 100 and 200 μg/mL submaximal protection dose) were selected for further mechanistic studies.

Acridine orange/ethidium bromide (AO/EB) staining was done on cells to find out the apoptotic index. In this study, the nuclear content of the apoptotic cells showed bright green fragmented color while it reflected red color in case of necrotized cells. Earlier studies demonstrated the apoptotic potential of PCM upon treatment in liver cells. Considering this, the cells were pre-treated with MK and challenged with PCM to assess the protection from the apoptotic inducing nature of PCM. The apoptotic bodies were seen in all the treatment groups, but MK treatment reduced the apoptotic index and thereby increased the cell viability. This showed that Megakutki protected the cells from PCM’s toxic insult. Similar changes were observed for standard silymarin.

Acute toxicity study showed that the formulation was safe at a single tested dose of 2000 mg/kg orally. Based on this and previous experience, two dose levels, 100 and 300 mg/kg were selected for hepatoprotection study in

![Figure 4: Histopathology of liver.](image)

4A: NORMAL, 4B: PCM, 4C: SLM plus PCM, 4D: MK100 plus PCM, 4E: MK300 plus PCM.

---

Table 3: Effect of Treatment on Antioxidant Levels.

<table>
<thead>
<tr>
<th>Group Name</th>
<th>Catalase</th>
<th>SOD</th>
<th>GSH</th>
<th>TBARS</th>
<th>Total thiols</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>8.3 ± 0.79</td>
<td>438.93 ± 9.9</td>
<td>6.54 ± 0.63</td>
<td>110.43 ± 4.19</td>
<td>18.09 ± 1.67</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>5.12 ± 0.4*</td>
<td>336.89 ± 15.27*</td>
<td>3.36 ± 0.38*</td>
<td>133.69 ± 6.19*</td>
<td>11.27 ± 0.47*</td>
</tr>
<tr>
<td>Silymarin – 50 mg/kg</td>
<td>8.43 ± 0.4*</td>
<td>438.01 ± 16.91*</td>
<td>7.02 ± 0.8*</td>
<td>105.18 ± 5.69*</td>
<td>15.65 ± 0.82*</td>
</tr>
<tr>
<td>Megakutki – 100 mg/kg</td>
<td>8.39 ± 0.6**</td>
<td>438.65 ± 11.03*</td>
<td>9.3 ± 0.84*</td>
<td>113.29 ± 6.23*</td>
<td>15.59 ± 0.64*</td>
</tr>
<tr>
<td>Megakutki – 300 mg/kg</td>
<td>9.45 ± 0.84*</td>
<td>499.86 ± 33.62*</td>
<td>9.21 ± 0.89*</td>
<td>106.87 ± 9.88*</td>
<td>19.24 ± 2.08*</td>
</tr>
</tbody>
</table>

All the values are Mean ± SEM, where #p<0.05 compared to normal control and *p<0.05 compared to PCM control.
Wistar rats against PCM. High levels of tannin and total phenol of MK can be the reason for this antioxidant potential. PCM is metabolized by cytochrome P450 enzymes to toxic metabolite NAPQI (N-acetyl- p-benzoquinone imine) that causes oxidative stress and glutathione (GSH) depletion which subsequently leads to lipid peroxidation and cellular damage. The major factor that is responsible for the toxicity is oxidative stress to the liver cells. The oxidative stress is a result of an inability of the natural antioxidant system of the body to cope up with the rise in the reactive oxygen species formation (ROS). When the antioxidant defence mechanism fails to prevent damage to the cells, the ROS damages macromolecules such as DNA, RNA, lipid, proteins and carbohydrates. In the present in-vivo model of PCM-induced toxicity, an increase in the liver enzyme levels as observed which confirmed hepatotoxicity.

At both dose levels of MK, the AST, ALT and ALP levels were significantly (p<0.05) reduced as compared to PCM without dose dependency. This revealed the significant hepatoprotective effect of MK in in-vivo study in Wistar rats. The reduction of the increased total bilirubin by Megakutki affirm that the drug exhibited hepatoprotective activity against PCM-induced toxicity. PCM decreased the endogenous antioxidant levels significantly with respect to the normal group. MK at 100 mg/kg and 300 mg/kg displayed significant (p<0.05) elevation of SOD, catalase and GSH levels compared to the disease control group while it also decreased the MDA level. However, MK did not show any dose-dependent antioxidant effect. This increase in antioxidant level and decrease in MDA level (a marker of oxidative stress) represented the hepatoprotective activity of MK against PCM intoxication through antioxidant mechanisms.

PCM can activate caspase 3 and result in apoptosis, which leads to the fragmentation of DNA. The DNA ladder assay showed DNA fragmentation, which confirms apoptosis by PCM. The drug treatment decreased the percentage of apoptosis and normalized the damage pattern.

CONCLUSION
MK showed a protective effect against PCM-induced hepatotoxicity with no evidence of toxicity. So, further clinical trials may be designed to assess the effect of MK in various liver disorders.

ACKNOWLEDGEMENT
We thank our institution Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, for providing infrastructural support.

CONFLICT OF INTEREST
We declare no conflict of interest. The Megakutki® was prepared by the authors from Umalaxmi Organics Private Limited, Jodhpur, India for commercial purpose.

ABBREVIATIONS
MK: Megakutki; PCM: Paracetamol; SOD: Superoxide dismutase; GSH: reduced glutathione; MDA: Malondialdehyde; AST: Aspartate transaminase; ALT: Alanine transaminase; ALP: Alkaline phosphatase; ROS: Reactive oxygen species formation; AO/EB: Acridine orange/ethidium bromide; CMC: Carboxymethylcellulose solution.

REFERENCES
Megakutki® (MK), polyherbal preparation containing known 11 standardized hepatoprotective extracts, was evaluated for its hepatoprotective effect against paracetamol (PCM) in in-vitro and in-vivo. The in-vitro studies on HepG2 cells showed significant protection by MK and silymarin against PCM in cell viability study and mechanistic studies (cell cycle analysis and apoptosis study). The in-vivo study was conducted in Wistar rats, where treatments of the vehicle (carboxymethylcellulose-0.25% w/v), silymarin and MK (100 and 300 mg/kg) were given for 8 days, while PCM (2.75 g/kg p.o.) challenge on the 6th day except for the vehicle control group. MK and silymarin reversed the altered liver function and oxidative stress markers levels (catalase, SOD, GSH, total thiols and lipid peroxidation) compared to PCM alone group. Both MK and silymarin decreased the percentage of DNA fragmentation and histopathological changes in liver tissue when compared to the PCM group. All these results have proven the hepatoprotection by MK and silymarin by inhibiting cell death and by preventing DNA damage against PCM challenge.
About Authors

Mrs. Asha Elizabeth Giri is a proud alumna of Manipal College of Pharmaceutical Sciences, MAHE, Manipal. She completed her master’s in pharmacology, in the year 2017, and joined as a Junior Associate Scientific writer at Indegene, Bangalore. At present, Mrs. Asha is working as a pharmacist in Canada. While pursuing the master’s degree, Mrs. Asha was vigorously involved in preclinical research, dedicated in the field of hepatotoxicity and molecular expression studies.

Ms. Vanishree Rao joined Manipal College of Pharmaceutical Science in the year 2019, as a research scholar. Her research interest is mainly in the area of computational drug design, neuroscience and hepatoprotection. Till now, she has co-authored 4 research articles in peer-reviewed indexed journals and 3 book chapters with the reputed publisher. Her present work is on exploring definitive pathways for the occurrence of chemoresistance in glioma patients.

Mr. Sandeep Singhal, is currently working as a Research Associate at Umalaxmi Organics Pvt. Ltd., and has been involved in research, development and manufacturing of standardized extracts contained in Megakutki, ensuring the highest quality standard of product for highest efficacy of a polyherbal formulation for liver disorders.

Mr. Karthik GouriShetti recently submitted synopsis for the doctoral thesis at Manipal College of Pharmaceutical Sciences, MAHE, Manipal. In 2019, he joined CSIR-Indian Institute of Chemical Technology, as a research associate. Mr. Karthik GouriShetti has extensively worked in the research areas like Diabetic wound healing, Chemo brain, NASH, Pulmonary fibrosis, Diabetes and has published plenty of his work in peer-reviewed journals.

Dr. Subhankar Biswas completed his Ph.D from Manipal College of Pharmaceutical Sciences, MAHE, Manipal. His area of research mainly includes computer-aided drug design, synthetic chemistry and cancer biology. He has published original and review articles at peer-reviewed journals and hold a patent on his name.

Dr. K. Nandakumar started his career as a Pharmacist in 1999. He completed his doctoral degree in Pharmaceutical Sciences in 2006. He is presently working as Professor at Manipal College of Pharmaceutical Sciences, MAHE. He is actively involved in research and has 90 Scopus-indexed publications, 2 awards and several Industry-academic research grants to his name. His area of research includes chemobrain, metabolic disorders and preclinical evaluation of drugs. He is a peer-reviewer for many leading journals and an editorial member of eCAM.

Dr. C. Mallikarjuna Rao completed his Ph.D in the year 1990. At present, he is leading the Manipal College of Pharmaceutical Sciences upfront as a principal since 2013. In total, he has 150 publications in national and international journals and has received 24 research funds. His area of research includes, wound healing, oncology, metabolic disorders and hepatotoxicity.

Jeetesh Dave, is working as Production director for the development of Kutki Raw material to final product Megakutki. He is taking an active interest in the development of herbal formulations for the treatment of various diseases. His supervision has led to the development of a range of products for Umalaxmi Organics Pvt. Ltd. with Megakutki one among them.

Rakesh Dave, In the Ayurvedic system of Medicine, Kutki is highly valued for its reputation providing strong hepatoprotective qualities, protect the heart and boost immunity and the Kutki extract (Megakutki) is organically cultivated and 100% pesticides free and contain all the active constituents such as kutkin, picroside and kutkoside and support Liver health plus centuries of safe use, are factors that create confidence with consumers and make it one of the popular ingredients for Liver health as explained by CEO Rakesh Dave. Rakesh Dave is actively involved in bringing out a range of herbal products for the treatment of various diseases.

Dr. Suhani Sumalatha, Ph.D, is currently working as an Assistant Professor in the Department of Anatomy at Kasturba Medical College Manipal, Manipal Academy of Higher Education, India. She has nearly 13 years of experience in teaching and research. She has to her credit nearly 50 research papers in reputed national and international journals. Her area of research interests includes clinical anatomy, experimental biology, traditional medicines and medical education.